

**FOI Request 11.19.51 - Number of Patients Treated**

Please detail the number of Oncology<sup>1</sup> patients treated<sup>2</sup> by your Trust with the stated therapies, during the time period **January 2019 to June 2019** inclusive.

	Total Number of Patients Treated:					
	Total Number of Patients Treated	Head & Neck Cancer	Adjuvant Melanoma	Metastatic Melanoma	Non-Small Cell Lung Cancer (NSCLC)	Renal Cell Carcinoma (RCC)
Pembrolizumab (Keytruda)	38	0	0	0	35	0
Nivolumab (Opdivo)	1	0	0	0	1	0
Ipilimumab (Yervoy)	0	0	0	0	0	0
Dabrafenib (Tafinlar)	0	0	0	0	0	0
Cabozantinib (Cabometyx)	0	0	0	0	0	0
Sunitinib (Sutent)	0	0	0	0	0	0
Pazopanib (Votrient)	0	0	0	0	0	0
Axitinib (Inlyta)	0	0	0	0	0	0
Atezolizumab (Tecentriq)	18	0	0	0	17	0
Sorafenib (Nexavar)	1	0	0	0	0	0
Tivozanib (Fotivda)	0	0	0	0	0	0
Lenvatinib (Lenvima)	0	0	0	0	0	0
Cetuximab (Erbix)	32	0	0	0	0	0
Everolimus (Afinitor)	8	0	0	0	0	0
Vemurafenib (Zelboraf)	0	0	0	0	0	0

1

Cancer Type	Diagnoses Codes (ICD10)
Head & Neck	C00-C14; C30-C32
Adjuvant Melanoma	C43 (treatment as additional treatment following primary)
Metastatic Melanoma	C43 plus C77, C78, C79
NSCLC	C34
RCC	C64

<sup>2</sup> Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).